Stifel lowered the firm’s price target on Black Diamond Therapeutics (BDTX) to $15 from $16 and keeps a Buy rating on the shares. The firm updated its model for the quarter, including the cash guidance, and made adjustments to near- to mid-term expense assumptions and the commercialization timeline given the prioritization of the first-line opportunity, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BDTX: